YourVoice.Now Summary
Corporate BenefitsTransparency & AccountabilityThe government would publish a list of must-have drugs — and track which come from just one supplier, here or overseas.
Corporate Benefits
HHS would have to lock down the data it gathers and shares. The point is to keep outsiders out of a company's plant sites and output numbers.
Today it is a crime for a federal official to reveal a company's trade secrets or output figures. The bill says agencies could pass that data to each other for this work without breaking that law. The data would still stay out of public records.
Transparency & Accountability
A list of essential medicines already exists under a 2020 executive order. A president can cancel that order at any time. The bill would put the duty in law, with a review at least every two years.
HHS would owe congressional committees a supply-chain risk report within 180 days, and one every year after. A second yearly report on the mapping work would start at 18 months.
The risk report would have to say where the government lacks the power to fix a supply problem. The mapping report would have to point out gaps, missing data, and doubled-up work inside HHS.
A 2020 executive order gave the Secretary several jobs on drug supply chains. One was to propose new rules for collecting data from drug makers. The bill would count the list work as fully meeting those duties.
More about this bill
What you pay for medicine would not change here. What would change is how much the government knows about where your medicine comes from. Health and Human Services would keep and publish a list of essential medicines. These are drugs the country cannot afford to run short of. The first update would be due within 180 days. HHS would also study and map the supply chains behind those drugs. It would have to name the drugs that lean on a foreign supplier for more than half of production. It would separately name drugs that come from just one supplier, foreign or American. Findings would go to congressional committees within 180 days, then every year. A second report, on the mapping work, would be due in 18 months. Neither report has to be made public. Drug companies would not have to file anything new.
Congressional Summary
Mapping America’s Pharmaceutical Supply Act or the MAPS Act This bill requires the Food and Drug Administration (FDA) to continually update its essential medicines list and identify risks and vulnerabilities in the associated supply chains. In 2020, in response to an executive order, the FDA published a list of essential medicines deemed medically necessary to have available at all times. The bill requires the FDA to update and maintain this list to include drugs and ingredients (1) related to responding to public health threats and emergency incidents, (2) that are of greatest priority for providing health care and are at high risk of shortage, and (3) the shortage of which would adversely affect patients with chronic conditions. The FDA must review the list at least every two years and update it as appropriate. Also, the bill requires the FDA to conduct a risk assessment of the supply chains for drugs and ingredients on the list and annually report its findings to Congress. The assessment must include information about key manufacturing materials, drugs with primarily foreign or single suppliers, manufacturing capacity, relevant public health and national security risks, and risk mitigation strategies. Additionally, the Department of Health and Human Services (HHS) must map and monitor relevant supply chains to identify vulnerabilities and provide an annual status report to Congress. HHS must facilitate the secure exchange of information among agencies regarding locations and quantities of production and relevant regulatory actions.
Legislative Subjects
Details
- Congress
- 119th
- Chamber
- House
- Status
- summarized
- Action
- Introduced in House
- Action Date
- 2025-06-26
- Date Added
- 2026-04-22
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.